	EPP-SOP-WU02
WCSB, Wageningen University	Version 1.1

EPP - Standard Operating Procedure

(only for selected experiments intended to transfer results from one lab to the other)

Title: Multiplex automated genome engineering (MAGE) for *Pseudomonas putida*

In vivo genome editing that uses synthetic ssDNA to introduce targeted modifications at multiple loci directly into the *Pseudomonas putida* chromosome in a cyclical manner for genome-wide editing.

distribution list			
changes to prior version: added a figure for the procedure section			
	name	signature	date
experimenter 1	Enrique Asín		04apr18
	García		

Instruction

Multiplex automated genome engineering (MAGE) for Pseudomonas putida

1 Introduction / Purpose

Multiplex automated genome engineering (MAGE) is a powerful technology which allows an investigator to create several independent or combinatorial genome modifications in a population of live cells.

MAGE harnesses phage homologous recombination proteins to generate targeted, fast, scarless modifications of bacterial chromosomes across many genomic loci. The recombinases used in MAGE act on synthetic ssDNA oligonucleotides introduced to a cell population which are designed with 5' – and 3' terminal homology arms that are complementary to target sequences in the chromosome. Oligos will anneal to their lagging strand of the target sequence during replication, and then they will be stably inherited after another round of replication. For a specific mutation, the oligo can skip, mispair or add bases respecting the target region, causing deletion, mismatch or insertion, respectively.

The technology is based on multiple cycles of recombineering using the *P. putida* characterized recombinase Rec2.

MAGE is aimed to genome-wide editing or for recoding projects that are not possible with other methods. In this case, our purpose is the recoding of the *P. putida* genome in which single nucleotide mutations have to be generated in hundreds of genes.

2 Equipment and chemicals

2.1 Equipment

- ⇒ Stationary incubator set at 30°C
- ⇒ Shaking incubator set at 30°C
- ⇒ Shaking water bath set at 42°C
- ⇒ Ice bucket
- ⇒ Centrifuge kept at room temperature
- ⇒ Microcentrifuge kept at room temperature
- ⇒ Electroporator
- ⇒ Electroporation cuvettes with 1mm
- ⇒ Thermal cycler
- ⇒ PCR tubes
- ⇒ Sterile 96-well culture plates
- \Rightarrow Single-channel pipettes for 0.5-5000 μ l volumes and sterile filter tips
- ⇒ Multichannel pipette for 0.5-200 µl volumes
- ⇒ Agarose gel electrophoresis apparatus
- ⇒ Sterile 1.7 ml microcentrifuge tubes
- ⇒ Sterile 50 ml culture tubes
- ⇒ Sterile Petri dishes
- \Rightarrow Inoculation hooks
- ⇒ Spectrophotometer
- ⇒ Spectrophotometer cuvettes

2.2 Chemicals

- User-defined synthetic ssDNA oligos for MAGE
- User-defined PCR primers for PCR
- Sterile distilled H₂O
- Tryptone
- Yeast extract
- Sodium chloride
- Agar
- Agarose
- DNA ladder
- Kanamycin
- Sucrose
- Nucleic acid stain: SYBR Safe

2.3. Bacterial strains

• *P. putida* strain: MAGE is performed in strains KT2440 or EM42 that carry the plasmid pSEVA251-clpL-Rec2-mutL36K

2.4. Other materials

- Plasmid pSEVA251-clpL-Rec2-mutL36K: contains a clpL temperature system which induces the
 expression of the recombinase gene Rec2 and the mutL36K gene which prevents the action of
 the mismatch repair system. ClpL system is induced at 42°C by inhibition of the repressor cl
 which is bounded to the pL promoter controlling the downstream genes at lower temperatures.
 The plasmid confers resistance to Kanamycin.
- User-defined synthetic ssDNA oligos for MAGE
- User-defined PCR primers for PCR

3. Media and buffers

3.1 LB (agar*)/Kn₅₀

- 10 g/l Tryptone
- 10 g/l NaCl
- 5 g/l Yeast Extract
- * 15 g/l Agar
- 50 ng/µl Kanamycin

3.2 TB/Kn₅₀

- 12 g/l Tryptone
- 24 g/l Yeast Extract
- 4 ml/l Glycerol
- 100 ml/l Phosphate buffer

3.3 Phosphate buffer

- 23.12 g/l KH₂PO₄
- 125.4 K₂HPO₄


3.4 Sucrose

- 300 mM Sucrose
- 4. Procedures

4.1 Cycle

- 1. Grow strain in LB/Kn $_{50}$ in a 30°C/250 rpm shaking incubator O/N.
- 2. Inoculate with the O/N culture 20 ml of fresh LB/Kn₅₀ at DO=0.1. Grow at 30°C/250 rpm until the cells reach mid-log phase, as measured by OD \approx 0.4-0.5 (approx. 2 h).
- 3. Induce the system by incubating at 42° C for 5 min in a water bath with shaking.
- 4. Place culture in ice for 5 min.
- 5. Competent cell preparation: wash cells with 300 mM Sucrose (10 ml, 5 ml, 1 ml) centrifuging at 4500 rpm/10 min between washes at RT. Resuspend cells in 200 µl 300 mM Sucrose.
- 6. Electroporate a 100 μl aliquot with 1 μl of recombineering oligonucleotide 100 μM (≈ 3 μg). For mutagenesis of more than one target site, a complex oligo pool is created by mixing the oligos that target separate loci. Generally, the final total oligo concentration in a complex pool is held at 1-20 μM, with each constituent contributing an equal amount. To create a 50-μl equimolar pool of n oligos at 20 μM aggregate concentration, (50/n)-μl volumes of each 20 μM stock would be mixed.
- 7. Inoculate electroporated cells in 5 ml of fresh TB/Kn₅₀ and let them recover for 1 h at 30° C/250 rpm in a shaking incubator.
- 8. Add 15 ml LB/Kn₅₀ to the inoculated 5 ml of TB/Kn₅₀ and incubate until cells reach OD=0.5. Cells take around 5 h to reach this OD, so only one cycle can be performed per day. Consequently, after the addition of the 15 ml of LB/Kn₅₀ it is recommended to incubate for at least 4 h at 30°C/250 rpm in a shaking incubator and after that place the cells in the fridge O/N (4 °C). Next day, cultures are reactivated again for 1-2 h at 30°C/250 rpm in a shaking incubator until they reach the desired OD (0.5). It is important to recover electroporated cultures long enough to allow at least two complete cycles of genome replication.
- 9. Repeat from step 3.

(A graphical work-flow for this procedure is shown below).



4.2 Checking of the mutations

- 1. Recover cells by incubating them at 30°C/250 rpm in a shaking incubator O/N instead of performing steps 8 and 9.
- 2. Prepare serial tenfold dilutions for each MAGE sample.
- 3. Spread 100 μ l of each dilution on plates selective for the mutagenized strain. Incubate the plates at 30°C O/N until colonies appear.
- 4. By using a multichannel pipette, fill each well of a 96-well culture plate with 150 μl of LB.
- 5. Use pipette tips to pick colonies from each sample, and then transfer each colony to one well of the 96-well plate.
- 6. Grow the picked colonies at 30° C/250 rpm in a shaking incubator until all wells have reached midlog phase, as measured by the OD₆₀₀.
- 7. Set up two PCRs for each isolated colony (MASC-PCR). To supply template DNA, add 1 μ l from each well of the 96-well plate to both WT and mutant reactions.
- 8. Visualize 4 μ l of each PCR product on an 1.5% (wt/vol) agarose gel to determine the genotype of each colony.
- 9. Freeze and store the pure cultures for the colonies that screened correctly, and then confirm genotype with Sanger sequencing.

5. Remarks/troubleshooting

5.1 General remarks

This protocol is currently under optimization.

5.2 Troubleshooting

- Arching during electroporation: Caused by residual salt in either the cell pellet or the introduced DNA could be solved by washing the cells one more time with 300 mM Sucrose.
- **No outgrowth during recovery:** Caused by too many cells killed by electroporation could be solved by washing the cells one more time with 300 mM Sucrose.
- **No colonies on either experiment or control plates:** Caused by poor MAGE ARF could be solved by carrying out more MAGE cyles and by inducing cells at proper OD₆₀₀.
- **Colonies on both experiment and negative control plates:** Caused by not enough antibiotics could be solved by preparing new plates with appropriate amount of antibiotics. Caused by contamination could be solved by re-streaking strains or starting from collected cells from a previous cycle.
- All PCR bands show the wild type: Caused by poor MAGE allelic replacement frequency could be solved by additional MAGE cycles. Cause by inadequate screen could be solved by screening more colonies.

6. Biosafety

No biosafety issues were associated with this protocol when applied to *Pseudomonas putida*. The protocol was developed and performed at an MLI /BSLII laboratory. The cycle experiments are performed in the flow cabinet to prevent contamination.

7. Acknowledgements



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 635536.